NKTR
NEKTAR THERAPEUTICS
NASDAQ · Healthcare · Biotechnology · US
$36.64
+2.40%0
Insider buys (3m)
2
Insider sells (3m)
-$43.5K
Net value (3m)
-44.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 25, 2026 | Ajer Jeffrey Robert · director | A-Award | 4,000 | $58 |
| Sep 25, 2026 | WHITFIELD ROY A · director | A-Award | 2,000 | $0.00 |
| Sep 25, 2026 | Ajer Jeffrey Robert · director | A-Award | 2,000 | $0.00 |
| Sep 25, 2026 | WHITFIELD ROY A · director | A-Award | 4,000 | $58 |
| Sep 25, 2026 | CHESS ROBERT · director | A-Award | 2,000 | $0.00 |
| Sep 25, 2026 | CHESS ROBERT · director | A-Award | 4,000 | $58 |
| Sep 25, 2026 | Brainard Diana · director | A-Award | 4,000 | $58 |
| Sep 25, 2026 | GREER R SCOTT · director | A-Award | 4,000 | $58 |
| Sep 25, 2026 | Brainard Diana · director | A-Award | 2,000 | $0.00 |
| Sep 25, 2026 | GREER R SCOTT · director | A-Award | 2,000 | $0.00 |
| Aug 20, 2026 | ROBIN HOWARD W · director, officer: President & CEO | Sale | 418 | $72 |
| Aug 20, 2026 | Zalevsky Jonathan · officer: Chief R&D Officer | Sale | 186 | $72 |
| Jul 24, 2026 | ROBIN HOWARD W · director, officer: President & CEO | A-Award | 57,200 | $15 |
| Jul 24, 2026 | Zalevsky Jonathan · officer: Chief R&D Officer | A-Award | 16,500 | $15 |
| Jul 2, 2026 | Zalevsky Jonathan · officer: Chief R&D Officer | Sale | 5,681 | $70 |
| Jun 18, 2026 | ROBIN HOWARD W · director, officer: President & CEO | Sale | 5,500 | $61 |
| Jun 18, 2026 | ROBIN HOWARD W · director, officer: President & CEO | Sale | 4,500 | $62 |
| Jun 18, 2026 | ROBIN HOWARD W · director, officer: President & CEO | Sale | 4,697 | $61 |
| Jun 18, 2026 | ROBIN HOWARD W · director, officer: President & CEO | Sale | 5,303 | $60 |
| Jun 17, 2026 | Zalevsky Jonathan · officer: Chief R&D Officer | Sale | 5,538 | $61 |
| May 21, 2026 | Zalevsky Jonathan · officer: Chief R&D Officer | Sale | 199 | $66 |
| May 21, 2026 | ROBIN HOWARD W · director, officer: President & CEO | Sale | 444 | $66 |
| Feb 20, 2026 | Zalevsky Jonathan · officer: Chief R&D Officer | Sale | 180 | $73 |
| Feb 20, 2026 | ROBIN HOWARD W · director, officer: President & CEO | Sale | 423 | $73 |
| Jan 22, 2026 | Zalevsky Jonathan · officer: Chief R&D Officer | Sale | 3,867 | $36 |
| Dec 23, 2025 | ROBIN HOWARD W · director, officer: President & CEO | A-Award | 21,667 | $0.00 |
| Dec 23, 2025 | ROBIN HOWARD W · director, officer: President & CEO | A-Award | 86,667 | $43 |
| Dec 23, 2025 | Zalevsky Jonathan · officer: Chief R&D Officer | A-Award | 25,000 | $43 |
| Dec 23, 2025 | Zalevsky Jonathan · officer: Chief R&D Officer | A-Award | 6,250 | $0.00 |
| Nov 25, 2025 | ROBIN HOWARD W · director, officer: President & CEO | Sale | 2,207 | $54 |
Institutional positioning
13F filings over the trailing two quarters
New 147Increased 179Reduced 86Sold out 43
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 5,067,920 | Aug 13, 2026 |
| FMR LLC | Increased | 4,303,188 | May 15, 2026 |
| Two Seas Capital LP | Increased | 3,345,978 | Oct 6, 2026 |
| Two Seas Capital LP | Increased | 3,092,234 | Aug 12, 2026 |
| BlackRock, Inc. | Increased | 2,941,851 | Aug 7, 2026 |
| BVF INC/IL | Increased | 2,559,595 | May 15, 2026 |
| BVF INC/IL | Reduced | 2,391,075 | Aug 14, 2026 |
| TWO SEAS CAPITAL LP | Increased | 1,959,178 | May 15, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Increased | 1,497,177 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 1,496,849 | Aug 13, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 1,202,004 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,197,055 | May 15, 2026 |
| Vestal Point Capital, LP | Increased | 1,000,000 | Aug 14, 2026 |
| MORGAN STANLEY | Increased | 936,560 | Aug 13, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 930,741 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 25, 2026